|Reference||Size||Price||Quantity||Add to cart|
The minimum purchase order quantity for the product is 1
ImmunoBead Assay for BCR/ABL human fusion protein detection. BCR–ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR–ABL aberrations of utmost importance for diagnosis, classification and treatment of leukemia patients.
1. F Weerkamp et. al Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients. Leukemia (2009) 23, 1106– 1117.
2. Mitelman F, Johansson B, Mertens F. The impact of translocationsand gene fusions on cancer causation. Nat Rev Cancer 2007; 7:233–245.
3. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765–767.
4. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurtsvan Kessel A, Bootsma D et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277–280.
5. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR,Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–99.
6. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536–1543.
7. Van Dongen JJM, Van der Velden VHJ, Berendes PB, Van Denderen AC. Recognition of tumour-specific gene products in cancer (Fusion protein bead patent). US6.686.165B2.
Tech Data Sheet